NCT05678725 is a NA clinical trial of tACS in tACS, sponsored by Anhui Medical University.

Who is sponsoring NCT05678725?

NCT05678725 is sponsored by Anhui Medical University.

What drugs are being tested in NCT05678725?

Interventions in NCT05678725: tACS, tDCS, sham.

What condition does NCT05678725 study?

NCT05678725 studies tACS, tDCS.

Is NCT05678725 still recruiting?

NCT05678725 is currently completed. Last updated 10 May 2024.

Last reviewed 2024-05-10 · How we verify

NCT05678725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment

Completed NA Last updated 10 May 2024

What this trial tests

NA trial testing tACS in tACS in 60 participants. Completed in 15 February 2024.

Timeline

15 February 2023

Primary endpoint
15 January 2024

15 February 2024

Quick facts

Lead sponsor	Anhui Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	15 February 2023
Primary completion	15 January 2024
Estimated completion	15 February 2024
Sites	1 location across China

Drugs / interventions tested

tACS
tDCS — full drug profile →
sham

Conditions studied

tACS — all drugs for tACS →
tDCS — all drugs for tDCS →

Sponsor

Anhui Medical University

Who can join

Adults 40 to 80, any sex, with tACS or tDCS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the difference in the treatment efficacy between transcranial direct current stimulation and transcranial alternating current stimulation on Parkinson's disease, including the improvements in the motor, cognitive, and underlying neural mechanisms behind differences in efficacy by electroencephalography (EEG).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Common and specific effects in brain oscillations and motor symptoms of tDCS and tACS in Parkinson's disease.
Liu J, Zhu Y, Chen B, Meng Q, et al · · 2025 · cited 7× · PMID 40154492 · DOI 10.1016/j.xcrm.2025.102044
Transcranial alternating current stimulation for neuropsychiatric disorders: a systematic review of treatment parameters and outcomes.
Gholamali Nezhad F, Martin J, Tassone VK, Swiderski A, et al · · 2024 · cited 7× · PMID 39211537 · DOI 10.3389/fpsyt.2024.1419243
ABSTRACTS
· 2025
Protocol for evaluating the effects of tDCS and tACS on brain oscillations and motor symptoms in patients with Parkinson's disease.
Liu J, Bu J. · · 2026 · PMID 41417739 · DOI 10.1016/j.xpro.2025.104245

Verify or expand the search:

Other trials of tACS

Trials testing the same drug.

NCT07185464 — Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) in Adolescents With First-episode Depression · NA · not yet recruiting
NCT07185451 — Efficacy and Safety of Transcranial Alternating Current Stimulation (tACS) Combined With Stable Medication in Adolescent · NA · not yet recruiting
NCT06211140 — Transcranial Alternating Current Stimulation (tACS) on Serotonin-1A Receptor in Depression · NA · unknown
NCT06208358 — A Study for the Disrupted Interpersonal Interaction Among Gaming Disorder Individuals and Treatment · NA · recruiting
NCT04986787 — Novel, Individualized Brain Stimulation, Network-based Approaches to Improve Cognition · NA · unknown

Other recruiting trials for tACS

Currently open trials in the same condition.

NCT05664412 — Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome · NA · recruiting

Other Anhui Medical University trials

Trials by the same sponsor.

NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
NCT07112612 — Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · not yet recruiting
NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05678725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
Last refreshed: 10 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing